Jsb Market Research : Opportunityanalyzer: Non-Hodgkins B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

OpportunityAnalyzer: Non-Hodgkins B-Cell Lymphoma Opportunity Analysis and Forecast to 2018

Released On 3rd September 2014

Summary

The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL), currently revolves around multiple rounds of Rituxan-based chemotherapy. Although patients can achieve durable remissions to induction therapy, those patients who relapse after primary treatment have poor prognosis and high unmet needs. Several promising pipeline agents are set to have a dramatic impact on treatment of these relapsed/refractory patients over the forecast period: Pharmacyclics’/Janssen’s Imbruvica, which was approved for relapsed/refractory

JSB Market Research Pvt. Ltd.

Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 / +91 - 998 729 5242 Published by- http:/www.jsbmarketresearch.com/

MCL patients in November 2013, Gilead’s Zydelig, which was approved for relapsed/refractory FL patients in July 2014, and Roche’s Gazyva, which will launch in 2015.

Highlights

Key Questions Answered

How will the launch of Imbruvica and Zydelig impact the treatment landscape of relapsed/refractory MCL and FL patients?

How will the launch of Gazyva and the subcutaneous formulation of MabThera help Roche protect their hematology franchise from biosimilar rituximab competition in the 5EU?

The new agents will launch first in one B-cell indication before seeking label expansion into broader NHL patient populations. How will companies expand their hematology candidates beyond their initial approvals?

Pharmacyclics has set a high pricing bar with a high ACOT for Imbruvica. How will this pricing strategy affect pricing of other...